The United Laboratories International Holdings Limited provided consolidated earnings guidance for the six months ended June 30, 2023. For the period, the Group is expected to record a net profit of approximately RMB 1,200,000,000 for the six months ended 30 June 2023, while the net profit for the six months ended 30 June 2022 is approximately RMB 629,000,000. The increase in profit is mainly contributed from the steady growth in turnover of each business segments of the Group during the period.

Among them, the sales of intermediate products and bulk medicines continue to increase. The rebound in demand represented by overseas markets has led to a steady rise in the market prices of related products. In addition, the sales of animal health products have increased significantly.

Total gross profit of the Group increases of approximately RMB 900,000,000.